IL150528A0 - Ibuprofen containing active agent preparation - Google Patents

Ibuprofen containing active agent preparation

Info

Publication number
IL150528A0
IL150528A0 IL15052801A IL15052801A IL150528A0 IL 150528 A0 IL150528 A0 IL 150528A0 IL 15052801 A IL15052801 A IL 15052801A IL 15052801 A IL15052801 A IL 15052801A IL 150528 A0 IL150528 A0 IL 150528A0
Authority
IL
Israel
Prior art keywords
active agent
containing active
agent preparation
ibuprofen
ibuprofen containing
Prior art date
Application number
IL15052801A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL150528A0 publication Critical patent/IL150528A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15052801A 2000-01-28 2001-01-19 Ibuprofen containing active agent preparation IL150528A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10003757A DE10003757A1 (de) 2000-01-28 2000-01-28 Ibuprofen-Wirkstoffzubereitung
PCT/EP2001/000602 WO2001054683A1 (de) 2000-01-28 2001-01-19 Ibuprofen-wirkstoffzubereitung

Publications (1)

Publication Number Publication Date
IL150528A0 true IL150528A0 (en) 2003-02-12

Family

ID=7629069

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15052801A IL150528A0 (en) 2000-01-28 2001-01-19 Ibuprofen containing active agent preparation
IL150528A IL150528A (en) 2000-01-28 2002-07-02 An active ingredient preparation containing ibuprofen

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150528A IL150528A (en) 2000-01-28 2002-07-02 An active ingredient preparation containing ibuprofen

Country Status (20)

Country Link
US (1) US20030045580A1 (hu)
EP (1) EP1250132B1 (hu)
JP (1) JP2003525223A (hu)
KR (1) KR100742489B1 (hu)
CN (1) CN1277535C (hu)
AT (1) ATE291908T1 (hu)
AU (1) AU784128B2 (hu)
BR (1) BR0107899A (hu)
CA (1) CA2398288A1 (hu)
CZ (1) CZ296485B6 (hu)
DE (2) DE10003757A1 (hu)
ES (1) ES2239119T3 (hu)
HU (1) HUP0204202A3 (hu)
IL (2) IL150528A0 (hu)
MX (1) MXPA02007076A (hu)
NO (1) NO20023551L (hu)
RU (1) RU2300368C2 (hu)
TW (1) TWI288641B (hu)
WO (1) WO2001054683A1 (hu)
ZA (1) ZA200206833B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
JP5248733B2 (ja) * 2003-11-28 2013-07-31 エスエス製薬株式会社 揮散防止型固形製剤およびその製造方法
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20060068009A1 (en) * 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
BRPI0503756A (pt) * 2005-09-06 2007-05-15 Gold Nutrition Pesquisa Desenv método de processamento de soja pelo uso de enzima especìfica, pó de soja processada e lìquido de soja processada
JP2009543885A (ja) 2006-07-18 2009-12-10 ホライゾン セラピューティクス， インコーポレイテッド イブプロフェンの投与のための方法および医薬
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
CN101646461A (zh) * 2007-03-13 2010-02-10 大日本住友制药株式会社 口腔崩解片
CN101829064B (zh) * 2010-04-27 2012-04-25 海南新中正制药有限公司 右旋布洛芬颗粒及其制备方法
MX344846B (es) * 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
KR20130030261A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 활성제-무함유 과립 및 그를 포함하는 정제의 제조
JP2010189443A (ja) * 2010-06-07 2010-09-02 Ss Pharmaceut Co Ltd 揮散防止型固形製剤およびその製造方法
CN102988322B (zh) * 2012-12-26 2014-09-03 合肥科大生物技术有限公司 一种精氨酸布洛芬片剂及其制备方法
US9615595B2 (en) 2013-03-05 2017-04-11 Mera Technology International Inc. Method and apparatus for wasteless homogenized soybean beverage production
EA030310B1 (ru) 2013-11-13 2018-07-31 Эро-Селтик С.А. Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
EP3694491A1 (en) 2017-10-10 2020-08-19 Capsugel Belgium NV Gelling multiparticulates
BR112023001716A2 (pt) * 2020-07-31 2023-04-04 Catalent Uk Swindon Zydis Ltd Composições farmacêuticas compreendendo api revestido

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4980375A (en) * 1987-07-10 1990-12-25 Sterling Drug Inc. Onset-hastened/enhanced antipyretic response
US4911921A (en) * 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
HUT59653A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing complexes containing s/+/-phenyl-alcanoic acids and alpha-hydroxy-alcanoic acids and pharmaceutical compositions containing them as active components
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US5191114A (en) * 1991-10-09 1993-03-02 Sage Pharmaceuticals, Inc. Process for enhancing the flow characteristics of ibuprofen
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
IT1270239B (it) * 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions

Also Published As

Publication number Publication date
DE50105771D1 (de) 2005-05-04
CZ296485B6 (cs) 2006-03-15
ZA200206833B (en) 2003-08-27
KR100742489B1 (ko) 2007-07-24
CN1400896A (zh) 2003-03-05
EP1250132A1 (de) 2002-10-23
DE10003757A1 (de) 2001-08-02
CZ20022605A3 (cs) 2003-02-12
KR20020069368A (ko) 2002-08-30
IL150528A (en) 2007-06-17
ATE291908T1 (de) 2005-04-15
BR0107899A (pt) 2002-11-05
HUP0204202A3 (en) 2003-04-28
AU784128B2 (en) 2006-02-09
NO20023551D0 (no) 2002-07-25
JP2003525223A (ja) 2003-08-26
NO20023551L (no) 2002-07-25
RU2300368C2 (ru) 2007-06-10
RU2002123182A (ru) 2004-03-20
AU3019701A (en) 2001-08-07
HUP0204202A2 (hu) 2003-03-28
CN1277535C (zh) 2006-10-04
EP1250132B1 (de) 2005-03-30
TWI288641B (en) 2007-10-21
WO2001054683A1 (de) 2001-08-02
MXPA02007076A (es) 2003-03-27
ES2239119T3 (es) 2005-09-16
CA2398288A1 (en) 2001-08-02
US20030045580A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
IL150528A0 (en) Ibuprofen containing active agent preparation
MXPA03007712A (es) Sales farmaceuticas.
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
AU2002227931A1 (en) Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as medicament, and pharmaceutical preparations containing these compounds
MXPA03004386A (es) Compuestos bis-arilo sustituidos en la posicion orto y meta, procesos para su preparacion, su uso como medicamento, y las preparaciones farmaceuticas que los contienen.
AU8178601A (en) Sustained release pharmaceutical compositions for the parenteral administration of biologically active hydrophilic compounds
MY125978A (en) Admantane derivatives
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
PL348419A1 (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
ZA200300777B (en) Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts.
AU2001241067A1 (en) Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient
GB0128071D0 (en) Medicament

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed